Antisense oligonucleotide technology is one of the most successful gene therapy (GT) approaches. However, low selectivity of antisense agents limits their application as anticancer drugs. To achieve activation of antisense agent selectively in cancer cells, herein, we propose the concept of binary antisense oligonucleotide (biASO) agent. biASO recognizes an RNA sequence of a gene associated with cancer development (marker) and then activates RNase H-dependent cleavage of a targeted messenger RNA. biASO was optimized to produce only the background cleavage of the targeted RNA in the absence of the activator. The approach lays the foundation for the development of highly selective and efficient GT agents.
XiongH, VeeduRN and Diermeier.SD (2021). Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci, 22:3295.
9.
KherG, TrehanS and MisraA. (2011). Antisense oligonucleotides and RNA interference. In: Challenges in Delivery of Therapeutic Genomics and Proteomics, 1st edn. Misra A, ed. Elsevier, London, pp 325–386.
10.
ShahryariA, IngoB, NazariZ and Lickert.H (2021). Engineering gene therapy: advances and barriers. Adv Ther, 4:2100040.
11.
MaCC, WangZL, XuT, HeZY and Wei.YQ (2020). The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv, 40:107502.
12.
LeBT, RaguramanP, KosbarTR, FletcherS, WiltonSD and VeeduRN. (2019). Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Mol Ther Nucleic Acids, 14:142–157.
13.
TakakuraK, KawamuraA and Torisu.Y (2019). The clinical potential of oligonucleotide therapeutics against pancreatic cancer. Int J Mol Sci, 20:3331.
14.
NedorezovaDD, FakhardoAF, MoldenTA and KolpashchikovDM. (2020). Deoxyribozyme-based DNA machines for cancer therapy. ChemBioChem, 21:607–611.
15.
DaoBN, ViardM, MartinsAN, KasprzakWK, ShapiroBA and AfoninKA. (2015). Triggering RNAi with multifunctional RNA nanoparticles and their delivery. DNA RNA Nanotechnol, 2:1–12.
16.
NedorezovaDD, FakhardoAF, NemirichDV, BryushkovaEA and KolpashchikovDM. (2019). Towards DNA nanomachines for cancer treatment: achieving selective and efficient cleavage of folded RNA. Angew Chem Int Ed, 58:4654–4658.
17.
MoldenTA, NiccumCT and KolpashchikovDM. (2020). Cut and paste for cancer treatment: a DNA nanodevice that cuts out an RNA marker sequence to activate a therapeutic function. Angew Chem Int Ed Engl, 59:21190–21194.
18.
WacheckV and Zangemeister-WittkeU. (2006). Antisense molecules for targeted cancer therapy. Crit Rev Oncol Hemat, 59:65–73.
19.
Palomino-VizcainoG and Alvarez-SalasLM. (2019). Therapeutic oligonucleotides against cancer: recent approaches and new perspectives. In: Nucleic Acid Nanotheranostics, 1st edn. Filice M and Ruiz-Cabelloeds J, eds. Elsevier, Amsterdam, Netherlands, pp 1–26.
20.
DeanNM and BennettCF. (2003). Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 22:9087–9096.
21.
ZhangK, LiY, LiuJ, YangX, XuY, ShiJ, LiuW and LiJ. (2020). Y-shaped circular aptamer–DNAzyme conjugates for highly efficient in vivo gene silencing. CCS Chem, 2:631–641.
22.
AlagiaA and EritjaR. (2016). siRNA and RNAi optimization. Wiley Interdiscip Rev RNA, 7:316–329.
KamphuesC, KadowakiS, AminiN, van den BergI, WangJ, AndreatosN, SakamotoY, OguraT, KakutaM, et al. (2021). The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: an international, multi-institutional study in patients with known KRAS, BRAF, and MSI status. J Surg Oncol, 123:1005–1014.
30.
ZanattoRM, SantosG, OliveiraJC, PracuchoEM, NunesAJF, Lopes-FilhoGJ and Saad.SS (2020). Impact of kras mutations in clinical features in colorectal cancer. ABCD. Arq Bras Cir Dig, 33:1524.
31.
ItoY, InoueE, MatsuiY, KobuchiS, MoyamaC, AmagaseK, YoshimuraM, IkeharaY, NakataS and NakanishiH. (2020). Cytology-based detection of circulating tumour cells in human pancreatic cancer xenograft models with KRAS mutation. Anticancer Res, 40:6781–6789.
32.
BurnsTF, BorghaeiH, RamalingamSS, MokTS and PetersS. (2020). Targeting KRAS-mutant non–small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations. J Clin Oncol, 38:4208–18.
33.
HobbsGA, DerCJ and RossmanKL. (2016). RAS isoforms and mutations in cancer at a glance. J Cell Sci, 129:1287–1292.
34.
StahelRA and Zangemeister-WittkeU. (2003). Antisense oligonucleotides for cancer therapy—an overview. Lung Cancer, 41:81–88.
35.
Crooke ST. (2000). Potential roles of antisense technology in cancer chemotherapy. Oncogene, 19:6651–6659.
36.
CarterG and LemoineNR. (1993). Antisense technology for cancer therapy: does it make sense?. Br J Cancer, 67:869.
37.
Aartsma-RusA. (2012). Overview on AON design. In: Exon Skipping, edn. Aartsma-Rus A, ed. Humana Press, New York, NY, pp 117–129.
38.
KoleR, KrainerAR and AltmanS. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov, 11:125–140.
39.
WongE and Goldberg.T (2014). Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. Pharm Ther, 39:119.
40.
Hoy SM. (2018). Patisiran: first global approval. Drugs, 78:1625–1631.
41.
LiS, JiangQ, LiuS, ZhangY, TianY, SongC, WangJ, ZouY, AndersonGJ, et al. (2018). A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat biotechnol, 36:258–264.
42.
StancescuM, FedotovaTA, HooyberghsJ, BalaeffA and KolpashchikovDM. (2016). Non-equilibrium hybridization enables discrimination of a point mutation within 5–40°C. J Am Chem Soc, 138:13465–13468.
43.
GerasimovaYV and KolpashchikovDM. (2012). Connectable DNA logic gates: OR and XOR logics. Chem Asian J, 7:534–540.
44.
OliveiraAGG, DubovichenkoMV, ElDeebAA, WanjohiJ, ZablotskayaS and KolpashchikovDM. (2021). RNA cleaving DNA thresholder controlled by concentrations of miRNA cancer marker. ChemBioChem, 22:1750–1754.
45.
KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
46.
MagnerD, BialaE, Lisowiec-WachnickaJ and KierzekR. (2017). Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes. Sci Rep, 7:1–16.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
